Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | PDE4A | P27815 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1270185 | 0.80 | LMNA (0.47) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Mannitol SCHEMBL20594083 | 0.75 | LMNA (1.00) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Mannitol SCHEMBL20567656 | 0.75 | LMNA (1.00) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Mannitol SCHEMBL13187369 | 0.75 | LMNA (1.00) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Adonitol SCHEMBL22572531 | 0.75 | LMNA (0.83) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Mannitol SCHEMBL23066399 | 0.75 | LMNA (1.00) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Xylitol SCHEMBL20594034 | 0.75 | LMNA (0.83) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Adonitol SCHEMBL20594035 | 0.75 | LMNA (0.83) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Mannitol SCHEMBL21837180 | 0.75 | LMNA (1.00) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Mannitol SCHEMBL20594082 | 0.75 | LMNA (1.00) | LMNAL3MBTL1TDP1KDM4EPDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100129385-A1 | IMMUNOGENIC MOLECULES | COUNCIL OF THE QUEENSLAND INSTITUTE OF MEDICAL RESEARCH, THE (AU) | 2010-05-27 | — | — | US | disclosed |
| EP-1861426-A4 | IMMUNOGENIC MOLECULES | QUEENSLAND INST MED RES (AU) | 2008-11-12 | — | — | EP | disclosed |
| EP-1861426-A1 | IMMUNOGENIC MOLECULES | THE COUNCIL OF THE QUEENSLAND INSTITUTE OF MEDICAL RESEARCH (AU) | 2007-12-05 | — | — | EP | disclosed |
| CN-1959378-A | Albumin combination mensuration reagent of ischemia modification | YIKANG TECH DEV CO LTD CHANGSH (CN) | 2007-05-09 | — | — | CN | disclosed |
| CN-1959377-A | Albumin combination mensuration reagent of ischemia modification, and method of application | YIKANG TECH DEV CO LTD CHANGSH (CN) | 2007-05-09 | — | — | CN | disclosed |
| WO-2006084319-A1 | IMMUNOGENIC MOLECULES | THE COUNCIL OF THE QUEENSLAND INSTITUTE OF MEDICAL RESEARCH (AU) | 2006-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100129385-A1 | IMMUNOGENIC MOLECULES | HLA-DRB1, HLA-C, CD74 | LMNA 4700/4885L3MBTL1 4021/4885TDP1 4277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.